全文获取类型
收费全文 | 5345篇 |
免费 | 390篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 154篇 |
妇产科学 | 122篇 |
基础医学 | 810篇 |
口腔科学 | 170篇 |
临床医学 | 403篇 |
内科学 | 1283篇 |
皮肤病学 | 133篇 |
神经病学 | 717篇 |
特种医学 | 129篇 |
外科学 | 480篇 |
综合类 | 7篇 |
一般理论 | 1篇 |
预防医学 | 364篇 |
眼科学 | 60篇 |
药学 | 392篇 |
中国医学 | 15篇 |
肿瘤学 | 486篇 |
出版年
2024年 | 10篇 |
2023年 | 58篇 |
2022年 | 169篇 |
2021年 | 256篇 |
2020年 | 147篇 |
2019年 | 218篇 |
2018年 | 229篇 |
2017年 | 141篇 |
2016年 | 199篇 |
2015年 | 222篇 |
2014年 | 269篇 |
2013年 | 331篇 |
2012年 | 508篇 |
2011年 | 464篇 |
2010年 | 261篇 |
2009年 | 213篇 |
2008年 | 312篇 |
2007年 | 313篇 |
2006年 | 332篇 |
2005年 | 240篇 |
2004年 | 253篇 |
2003年 | 204篇 |
2002年 | 171篇 |
2001年 | 25篇 |
2000年 | 12篇 |
1999年 | 39篇 |
1998年 | 38篇 |
1997年 | 23篇 |
1996年 | 22篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 11篇 |
1992年 | 8篇 |
1991年 | 2篇 |
1990年 | 7篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1985年 | 1篇 |
1984年 | 7篇 |
1983年 | 2篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1943年 | 1篇 |
1921年 | 1篇 |
排序方式: 共有5767条查询结果,搜索用时 31 毫秒
61.
Federico Boscari Martina Vettoretti Anna Maria Letizia Amato Valeria Vallone Ambra Uliana Elisabetta Iori Angelo Avogaro Andrea Facchinetti Daniela Bruttomesso 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(2):650-657
Background and aimsContinuous glucose monitoring improves glycemic control in diabetes. This study compared the accuracy of the Dexcom G5 Mobile (Dexcom, San Diego, CA) transcutaneous sensor (DG5) and the first version of Eversense (Senseonics,Inc., Germantown, MD) implantable sensor (EVS).Methods and resultsSubjects with type 1 diabetes (T1D) and using EVS wore simultaneously DG5 for seven days. At day 3, patients were admitted to a clinical research center (CRC) to receive breakfast with delayed and increased insulin bolus to induce glucose excursions. At CRC, venous glucose was monitored every 15 min (or 5 min during hypoglycemia) for 6 h by YSI 2300 STAT PLUS? glucose and lactate analyzer. At home patients were requested to perform 4 fingerstick glucose measurements per day.Eleven patients (9 males, age 47.4 ± 11.3 years, M±SD) were enrolled. During home-stay the median [25th-75th percentile] absolute relative difference (ARD) over all CGM-fingerstick matched-pairs was 11.64% [5.38–20.65]% for the DG5 and 10.75% [5.15–19.74]% for the EVS (p-value = 0.58). At CRC, considering all the CGM-YSI matched-pairs, the DG5 showed overall smaller median ARD than EVS, 7.91% [4.14–14.30]% vs 11.4% [5.04–18.54]% (p-value<0.001). Considering accuracy during blood glucose swings, DG5 performed better than EVS when glucose rate-of-change was ?0.5 to ?1.5 mg/dL/min, with median ARD of 7.34% [3.71–12.76]% vs 13.59% [4.53–20.78]% (p-value<0.001), and for rate-of-change < -1.5 mg/dl/min, with median ARD of 5.23% [2.09–15.29]% vs 12.73% [4.14–20.82]% (p-value = 0.02).ConclusionsDG5 was more accurate than EVS at CRC, especially when glucose decreased. No differences were found at home. 相似文献
62.
63.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
64.
65.
66.
Fabrizio Rao Giancarlo Garuti Michele Vitacca Paolo Banfi Fabrizio Racca Renato Cutrera Martino Pavone Marina Pedemonte Matteo Schisano Stefania Pedroni Jacopo Casiraghi Andrea Vianello Valeria A Sansone UILDM Respiratory group 《Acta myologica》2021,40(1):8
Respiratory complications are common in the patient with muscular dystrophy. The periodic clinical and instrumental respiratory evaluation is extremely important. Despite the presence in the literature of updated guidelines, patient associations often report lack of knowledge of these pathologies, particularly in peripheral hospitals. The purpose of this work, inspired by the Italian Muscular Dystrophy Association (UILDM) is to improve management of respiratory problems necessary for the management of these patients complex. To this end, the main items that the specialist can meet in the follow-up of these pathologies have been analyzed and discussed, among which the respiratory basal evaluation, the criteria of adaptation to non-invasive ventilation, management of bronchial secretions, situations of respiratory emergency, indications for tracheostomy and the subject of advance directives of treatment (DAT).Key words: respiratory failure, muscular dystrophy, cough efficacy, spirometry, polygraphy, non-invasive ventilation, arterial blood gases, cough machine, invasive ventilation, tracheostomy, mechanical ventilation 相似文献
67.
68.
69.
Alberto Führer-Valdivia Alfredo Noguera-Pantoja Valeria Ramírez-Lobos Pedro Solé-Ventura 《Medicina oral, patología oral y cirugía bucal》2014,19(4):e327-e334
Objectives: Evaluate the effect on the application of low level laser therapy, in patients that have been previously intervened with a sagittal ramus split osteotomy and present neurosensory impairment due to this surgery, compared with placebo.
Study Design: This preliminary study is a randomized clinical trial, with an experimental group (n=17) which received laser light and a control group (n=14), placebo. All participants received laser applications, divided after surgery in days 1, 2, 3, 5, 10, 14, 21 and 28. Neurosensory impairment was evaluated clinically with 5 tests; visual analog scale (VAS) for pain and sensitivity, directional and 2 point discrimination, thermal discrimination, each one of them performed before and after surgery on day 1, and 1, 2 and 6 months. Participants and results evaluator were blinded to intervention. Variables were described with absolute frequencies, percentages and medians. Ordinal and dichotomous variables were compared with Mann Whitney’s and Fisher’s test respectively.
Results: Results demonstrate clinical improvement in time, as well as in magnitude of neurosensory return for laser group; VAS for sensitivity reached 5 (normal), 10 participants recovered initial values for 2 point discrimination (62,5%) and 87,5% recovered directional discrimination at 6 months after surgery. General VAS for sensitivity showed 68,75% for laser group, compared with placebo 21,43% (p-value = (0.0095). Left side sensitivity (VAS) showed 3.25 and 4 medians for placebo and laser at 2 months, respectively (p-value = (0.004).
Conclusions: Low-level laser therapy was beneficial for this group of patients on recovery of neurosensory impairment of mandibular nerve, compared to a placebo.
Key words:Laser Therapy, low-level, LLLP, osteotomy, sagittal split ramus, paresthesia, mandibular nerve. 相似文献
70.